



11th Paris Hepatology Conference 2018

Palais des Congrès

Paris 15,16 January 2018

Hepatitis C in Italy

Massimo Colombo, MD

Center for Translational Research in Hepatology, Humanitas Hospital, Rozzano, Italy.

EASL International Liver Foundation, Geneva, Switzerland

Financial Disclosures

Grant and research support: BMS, Gilead Science

Advisory committees: Merck, Roche, Novartis, Bayer, BMS, Gilead Science,
Tibotec, Vertex, Janssen Cilag, Achillion, Lundbeck, GSK,
GenSpera, AbbVie, Alfa Wasserman

Speaking and teaching: Tibotec, Roche, Novartis, Bayer, BMS, Gilead
Science, Vertex, Merck, Janssen, AbbVie

Current Situation of Hepatitis C in Italy

- 0.8% HCVRNA infected general population
 - > 300,000 HCV carriers in NHS claims registry
 - 10,000 deaths x year
 - > 500 LT per year due to end-stage hepatitis C
 - Total treated with DAA = 109,428 on Jan 1st 2018
 - Total treated in 2017 = 45,201
-

Current Resources and Programs for HCV in Italy

- Eu 2.5 billion between 2014-2017
 - Sof-Vel ,Gle-Pib,Elb-Grz to be reimbursed by NHS
 - Targeted screening (blood donors)
 - Access to treatment: severity criteria lifted & reduced price
-

Future Actions Planned

- Regional plans,i.e. screening of migrants targeting Sicily
 - Regional plans to facilitate access(Veneto,Lombardy,Sicily)
 - Triplet (NS5b,NS5a,PI)
 - Implementation of Viral Hepatitis National Plan including a nationwide registry
-